BT-001 rectacl cancer
Category: BT-001
Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors
ESMO Poster
Updated clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb,administered in combination with pembrolizumab in patients with advanced solid tumors
C. Lebbe, et al. ESMO 2025 Abstract available on ESMO website – Download the abstract – Download the Poster
Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025
ESMO Abstract
Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001 at ESMO 2025
ESMO 2025
Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors
S. Champiat, et al. ESMO 2024 Abstract available on the ESMO website – Download the abstract and the poster
Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatment
BT-001 ESMO
Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024
ESMO ABSTRACT
Transgene and BioInvent to Present Poster on Oncolytic Virus, BT-001, at ESMO 2024
BT-001 ESMO 2024
Transgene and BioInvent – First patient treated in Part B of Phase I trial assessing the novel oncolytic virus BT-001 in combination with KEYTRUDA®(pembrolizumab)
Transgene and BioInvent – first patient treated in Part B of Phase I trial